Teknova

Teknova

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

Teknova is a specialized reagent manufacturer providing critical consumables to the biotech, diagnostics, and therapeutic development sectors. With nearly three decades of operation, the company leverages its ISO 13485-certified facilities to offer over 1,400 ready-to-ship products and extensive custom manufacturing services, emphasizing flexibility, quality, and speed. Its business model is built on supporting customers from research through clinical manufacturing, helping to streamline scale-up and tech transfer processes. Teknova's strategic positioning in high-growth areas like cell and gene therapy and synthetic biology underpins its market opportunity.

Diagnostics

Technology Platform

Modular, scalable manufacturing infrastructure for RUO and GMP-grade liquid and solid reagents, with expertise in custom formulation, flexible formatting (tubes to single-use bags), and rigorous QC testing. Specialized systems for cryopreservation (PluriFreeze) and AAV production (AAV•Tek).

Funding History

2
Total raised:$40M
Series B$25M
Series A$15M

Opportunities

Strong tailwinds from the growth of cell and gene therapies and molecular diagnostics, which require high-quality, regulated reagents.
The introduction of intermediate grades (RUO+) and expedited services (Express•Tek) directly addresses customer needs for faster, de-risked scale-up from research to clinical manufacturing.

Risk Factors

Dependence on the financial health and R&D spending of biotech customers.
Risks include supply chain disruptions for raw materials, intense competition from larger conglomerates, and the constant need to maintain stringent quality and regulatory compliance across operations.

Competitive Landscape

Competes with large, diversified life science suppliers (e.g., Thermo Fisher Scientific, Merck KGaA, Danaher) and smaller niche reagent manufacturers. Differentiation is achieved through high-touch custom services, rapid turnaround times, a focus on flexible formatting, and targeted expertise in areas like cell therapy and synthetic biology.